Literature DB >> 26768643

A Comparison of IHC and FISH Cytogenetic Methods in the Evaluation of HER2 Status in Breast Cancer.

Marta Wesoła1, Michał Jeleń1.   

Abstract

The HER2 gene is responsible for the formation of the HER2 receptor on the surface of epithelial cells. Increased numbers of this receptor are associated with a worse prognosis in cancer. Increased numbers of copies of the HER2 gene occur in about 20-30% of breast cancer patients, so determining HER2 receptor levels is important in the current diagnosis and treatment of breast cancer. One diagnostic technique is the immunohistochemical (IHC) method, which permits indirect measurement of overexpression of HER2 receptors, based on subjective determination of the intensity of the color reaction. Another technique is the use of fluorescent in situ hybridization (FISH), which permits the exact number of copies of the HER2 gene to be specified. Based on the results of FISH tests, patients can be qualified for treatment with antibodies that partially block HER2 receptors. This treatment causes inhibition of tumor growth signals. Determining the HER2 status in breast cancer with the FISH method allows the further progress of the disease to be predicted, the right treatment to be chosen and the response to the treatment to be foreseen. Because of the widespread use of the FISH and IHC methods, comparing the advantages and disadvantages of these two methods seems to be relevant.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26768643     DOI: 10.17219/acem/27923

Source DB:  PubMed          Journal:  Adv Clin Exp Med        ISSN: 1899-5276            Impact factor:   1.727


  10 in total

1.  Discovering Pair-wise Synergies in Microarray Data.

Authors:  Yuan Chen; Dan Cao; Jun Gao; Zheming Yuan
Journal:  Sci Rep       Date:  2016-07-29       Impact factor: 4.379

Review 2.  Molecular Mechanisms and Translational Therapies for Human Epidermal Receptor 2 Positive Breast Cancer.

Authors:  Quanxia Lv; Ziyuan Meng; Yuanyuan Yu; Feng Jiang; Daogang Guan; Chao Liang; Junwei Zhou; Aiping Lu; Ge Zhang
Journal:  Int J Mol Sci       Date:  2016-12-14       Impact factor: 5.923

Review 3.  Potential Diagnostic and Therapeutic Applications of Oligonucleotide Aptamers in Breast Cancer.

Authors:  Xiaoqiu Wu; Atik Badshah Shaikh; Yuanyuan Yu; Yongshu Li; Shuaijian Ni; Aiping Lu; Ge Zhang
Journal:  Int J Mol Sci       Date:  2017-08-25       Impact factor: 5.923

4.  A Tri-part Protein Complementation System Using Antibody-Small Peptide Fusions Enables Homogeneous Immunoassays.

Authors:  Andrew S Dixon; Sun Jin Kim; Brett K Baumgartner; Sylvia Krippner; Shawn C Owen
Journal:  Sci Rep       Date:  2017-08-15       Impact factor: 4.379

5.  Associations between pathologic tumor features and preadjuvant therapy cognitive performance in women diagnosed with breast cancer.

Authors:  Theresa A Koleck; Catherine M Bender; Susan M Sereika; Christopher M Ryan; Puja Ghotkar; Adam M Brufsky; Rachel C Jankowitz; Priscilla F McAuliffe; Beth Z Clark; Yvette P Conley
Journal:  Cancer Med       Date:  2017-01-13       Impact factor: 4.452

Review 6.  Use of Fluorescence In Situ Hybridization (FISH) in Diagnosis and Tailored Therapies in Solid Tumors.

Authors:  Natalia Magdalena Chrzanowska; Janusz Kowalewski; Marzena Anna Lewandowska
Journal:  Molecules       Date:  2020-04-17       Impact factor: 4.411

Review 7.  Targeted therapeutic options and future perspectives for HER2-positive breast cancer.

Authors:  Jiani Wang; Binghe Xu
Journal:  Signal Transduct Target Ther       Date:  2019-09-13

8.  An insight into the invasion of breast ductal carcinoma in situ based on clinical, pathological and hematological data.

Authors:  Yanbiao Liu; Zining Jin; Xinmiao Yu; Ang Zheng; Feng Jin; Xu Wang
Journal:  PeerJ       Date:  2022-08-31       Impact factor: 3.061

9.  High performance of targeted next generation sequencing on variance detection in clinical tumor specimens in comparison with current conventional methods.

Authors:  Dan Su; Dadong Zhang; Kaiyan Chen; Jing Lu; Junzhou Wu; Xinkai Cao; Lisha Ying; Qihuang Jin; Yizhou Ye; Zhenghua Xie; Lei Xiong; Weimin Mao; Fugen Li
Journal:  J Exp Clin Cancer Res       Date:  2017-09-07

10.  Elevated serum HER-2 predicts poor prognosis in breast cancer and is correlated to ADAM10 expression.

Authors:  Hui Zheng; Ailing Zhong; Suhong Xie; Yanchun Wang; Jiajun Sun; Jie Zhang; Ying Tong; Miaomiao Chen; Guihong Zhang; Qian Ma; Jinyan Kai; Lin Guo; Renquan Lu
Journal:  Cancer Med       Date:  2019-01-19       Impact factor: 4.452

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.